Gastrointestinal stromal tumors of the stomach

Surg Oncol Clin N Am. 2012 Jan;21(1):21-33. doi: 10.1016/j.soc.2011.09.008.

Abstract

Gastrointestinal stromal tumors (GISTs) are relatively rare mesenchymal tumors located within the submucosa of the GI tract. The defining characteristic of GISTs is the presence of the cell-surface antigen CD117 receptor tyrosine kinase, identified by immunohistochemistry. Currently the only cure for GIST is complete surgical resection. Imatinib has revolutionized the treatment of GISTs and has been used as adjuvant treatment after resection, and as treatment for locally advanced, recurrent, and metastatic GIST. Imatinib resistance has become a significant concern in the treatment of GISTs and other tyrosine kinase inhibitors that target different pathways are currently being studied.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Chemotherapy, Adjuvant / methods
  • Drug Resistance, Neoplasm
  • Gastrointestinal Stromal Tumors / genetics
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / therapy*
  • Gastroscopy / methods
  • Humans
  • Imatinib Mesylate
  • Indoles / therapeutic use
  • Laparoscopy / methods
  • Mutation / genetics
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-kit / genetics
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Radiotherapy, Adjuvant / methods
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy*
  • Sunitinib

Substances

  • Antineoplastic Agents
  • Benzamides
  • Indoles
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Pyrroles
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit
  • Sunitinib